South African study: New COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy

New COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy The new COVID-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, scientists said on Wednesday. Reuters Staff U.S.

JOHANNESBURG (Reuters) - The new COVID-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, scientists said on Wednesday.

Researchers are racing to establish whether the vaccines currently being rolled out across the globe are effective against the so-called 501Y.V2 variant, identified by South African genomics experts late last year in Nelson Mandela Bay.

“This lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies,” the team of scientists from three South African universities working with the National Institute for Communicable Diseases (NICD) wrote in a paper published in the bioRxiv journal.

“Furthermore, 501Y.V2 shows substantial or complete escape from neutralising antibodies in COVID-19 convalescent plasma,” they wrote, adding that their conclusions “highlight the prospect of reinfection ... and may foreshadow reduced efficacy of current spike-based vaccines.”   

See: https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1